These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 24321157)
1. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis. Ožura A; Kovač L; Sega S Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S6-11. PubMed ID: 24321157 [TBL] [Abstract][Full Text] [Related]
2. Medication adherence with disease modifying treatments for multiple sclerosis among US employees. Kleinman NL; Beren IA; Rajagopalan K; Brook RA J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113 [TBL] [Abstract][Full Text] [Related]
3. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States. Bonafede MM; Johnson BH; Wenten M; Watson C Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422 [TBL] [Abstract][Full Text] [Related]
4. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Lugaresi A; Rottoli MR; Patti F Expert Rev Neurother; 2014 Sep; 14(9):1029-42. PubMed ID: 25109614 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study. Saiz A; Mora S; Blanco J; Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756 [TBL] [Abstract][Full Text] [Related]
6. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722 [TBL] [Abstract][Full Text] [Related]
7. Adherence to Web-Based Self-Assessments in Long-Term Direct-to-Patient Research: Two-Year Study of Multiple Sclerosis Patients. Jongen PJ; Kremer IEH; Hristodorova E; Evers SMAA; Kool A; van Noort EM; Hiligsmann M J Med Internet Res; 2017 Jul; 19(7):e249. PubMed ID: 28733272 [TBL] [Abstract][Full Text] [Related]
8. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Turner AP; Kivlahan DR; Sloan AP; Haselkorn JK Mult Scler; 2007 Nov; 13(9):1146-52. PubMed ID: 17967842 [TBL] [Abstract][Full Text] [Related]
9. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Cohen BA; Coyle PK; Leist T; Oleen-Burkey MA; Schwartz M; Zwibel H Mult Scler Relat Disord; 2015 Jan; 4(1):75-82. PubMed ID: 25787057 [TBL] [Abstract][Full Text] [Related]
10. Factors associated with adherence to disease modifying therapy in multiple sclerosis: An observational survey from a referral center in Lithuania. Duchovskiene N; Mickeviciene D; Jurkeviciene G; Dirziuviene B; Balnyte R Mult Scler Relat Disord; 2017 Apr; 13():107-111. PubMed ID: 28427690 [TBL] [Abstract][Full Text] [Related]
11. Adherence to Disease-Modifying Therapies for Multiple Sclerosis. Higuera L; Carlin CS; Anderson S J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830 [TBL] [Abstract][Full Text] [Related]
12. Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ). Wicks P; Massagli M; Kulkarni A; Dastani H J Med Internet Res; 2011 Jan; 13(1):e12. PubMed ID: 21266318 [TBL] [Abstract][Full Text] [Related]
13. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Tan H; Cai Q; Agarwal S; Stephenson JJ; Kamat S Adv Ther; 2011 Jan; 28(1):51-61. PubMed ID: 21153000 [TBL] [Abstract][Full Text] [Related]
14. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study. Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144 [TBL] [Abstract][Full Text] [Related]
15. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Bruce JM; Hancock LM; Lynch SG Mult Scler; 2010 Jan; 16(1):112-20. PubMed ID: 19995835 [TBL] [Abstract][Full Text] [Related]
16. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169 [TBL] [Abstract][Full Text] [Related]
17. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. McKay KA; Tremlett H; Patten SB; Fisk JD; Evans C; Fiest K; Campbell T; Marrie RA; Mult Scler; 2017 Apr; 23(4):588-596. PubMed ID: 27357507 [TBL] [Abstract][Full Text] [Related]
18. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US. Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190 [TBL] [Abstract][Full Text] [Related]
19. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study. Al-Keilani MS; Almomani BA Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264 [TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Wingerchuk DM; Carter JL Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]